Magle Chemoswed Holding AB announced that AXXO® Woundgel has received regulatory approval in Kuwait. The product is intended for the prevention and treatment of wound infections. Magle Group has already delivered the first commercial batch of AXXO® Woundgel to its distribution partner, AXXO, ahead of the upcoming product launch in Kuwait.

AXXO® Woundgel (also marketed as SmartGEL®) is a non-allergenic hydrogel based on Magle Group's proprietary polymer technology, DSM® (Degradable Starch Microsphere). The product contains antimicrobials incorporated into fully biodegradable starch microspheres, which are suspended in a gel matrix for optimal infection prevention and treatment. The gel delivers moisture to the wound, whilst maintaining enough absorption capacity for exudate, debris and bacteria.

Magle Group is striving to continuously increase its revenues from existing DSM® products, both through intensified and geographically broadened direct sales activities and in alliances for marketing and distribution. In parallel, the company is pursuing the development of additional DSM® products through carefully balanced investments, with new market launches projected in the coming years.